Tanja Gagliardi, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the need for development of modalities that can better identify a complete response in breast cancer, to aid the selection of optimal neoadjuvant treatment for individual patients. Dr Gagliardi talks on how imaging techniques, radiomics and artificial intelligence could be combined to come up with a better prediction of complete response. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
